Nian Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nian Zhu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Bo Liu
School of Mathematical and Computational Sciences, Massey University, Auckland, New Zealand
4 shared publications - Junqi Long
School of Software Engineering, Faculty of Information Technology, Beijing University of Technology, Beijing, China
4 shared publications - Shuangtao Zhao
Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, China
4 shared publications - Xinchan Ji
School of Software Engineering, Faculty of Information Technology, Beijing University of Technology, Beijing, China
4 shared publications - Huina Wang
School of Computer Science, Beijing University of Technology, Beijing 100124, China
3 shared publications - Jinmeng Li
School of Software Engineering, Faculty of Information Technology, Beijing University of Technology, Beijing 100124, China
3 shared publications
Latest Publications
- 3 October 2023
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (4) , 936-950
Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle
Background Diffuse large B-cell lymphoma (DLBCL) exhibits remarkable heterogeneity but still remains undiagnosed in identifying the subpopulation of DLBCL to predict the prognosis and guide clinical treatment. Methods Molecular subgroups were identified in gene expression data from GSE10846 by a consensus clustering algorithm. And gene set enrichment analysis, immune infiltration, and the proposed cell cycle algorithm were applied to explore the biological functions of different subtypes. Meanwhile, univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors of DLBCL. Finally, the prognostic model, including some key genes screened by Lasso regression, Random Forest algorithm, and point-biserial correlation, was constructed by an optimal classifier from seven machine learning algorithms and validated by another three external datasets (GSE34171, GSE87371, GSE31312). Results Comprehensive genomic analysis of 1,143 DLBCL samples identify 2 molecularly, prognostically relevant subtypes: immune-enriched (IME) and cell-cycle-enriched (CCE). Then a new predictive model including seven key genes (SERPING1, TIMP2, NME1, DCTPP1, RFC4, POLE2, and SNRPD1) was developed with high prediction accuracy (88.6%) and strong predictive power (AUC = 0.973) based on the Support Vector Machine (SVM) algorithm in 414 patients from GSE10846. The predictive power was similar in another three testing sets (HR > 1.400, p < 0.05). Conclusion This model could evaluate survival independently with strong predictive power compared with other clinical risk factors. Our study constructed a reliable model to predict two new subtypes of DLBCL patients, which could guide the implementation of individualized treatment.
- 3 October 2023
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (4) , 936-950
Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle
Background Diffuse large B-cell lymphoma (DLBCL) exhibits remarkable heterogeneity but still remains undiagnosed in identifying the subpopulation of DLBCL to predict the prognosis and guide clinical treatment. Methods Molecular subgroups were identified in gene expression data from GSE10846 by a consensus clustering algorithm. And gene set enrichment analysis, immune infiltration, and the proposed cell cycle algorithm were applied to explore the biological functions of different subtypes. Meanwhile, univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors of DLBCL. Finally, the prognostic model, including some key genes screened by Lasso regression, Random Forest algorithm, and point-biserial correlation, was constructed by an optimal classifier from seven machine learning algorithms and validated by another three external datasets (GSE34171, GSE87371, GSE31312). Results Comprehensive genomic analysis of 1,143 DLBCL samples identify 2 molecularly, prognostically relevant subtypes: immune-enriched (IME) and cell-cycle-enriched (CCE). Then a new predictive model including seven key genes (SERPING1, TIMP2, NME1, DCTPP1, RFC4, POLE2, and SNRPD1) was developed with high prediction accuracy (88.6%) and strong predictive power (AUC = 0.973) based on the Support Vector Machine (SVM) algorithm in 414 patients from GSE10846. The predictive power was similar in another three testing sets (HR > 1.400, p < 0.05). Conclusion This model could evaluate survival independently with strong predictive power compared with other clinical risk factors. Our study constructed a reliable model to predict two new subtypes of DLBCL patients, which could guide the implementation of individualized treatment.
- Open Access
- 12 December 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-17
A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer
Background. Currently, predictive models were not developed based on the signaling pathway signatures of immune-related lncRNAs in breast cancer (BRCA) patients. Methods. We selected unsupervised hierarchical clustering algorithm to classify patients with BRCA based on the significant immune-derived lncRNAs from the TCGA dataset. And different methods including ESTIMATE, ImmuneCellAI, and CIBERSORT were performed to evaluate the immune infiltration of tumor microenvironment. Using Lasso regression algorithm, we filtered the significant signaling pathways enriched by GSEA, GSVA, or PPI analysis to develop a prognostic model. And a nomogram integrated with clinical factors and significant pathways was constructed to predict the precise probability of overall survival (OS) of BRCA patients in the TCGA dataset (n = 1,098) and another two testing sets (n = 415). Results. BRCA patients were stratified into the PC (n = 571) and GC (n = 527) subgroup with significantly different prognosis with 550 immune-related lncRNAs in the TCGA dataset. Integrated analysis revealed different immune response, oncogenic signaling, and metabolic reprograming pathways between these two subgroups. And a 5-pathway signature could predict the prognosis of BRCA patients between these two subgroups independently in the TCGA dataset, which was confirmed in another two cohorts from the GEO dataset. In the TCGA dataset, 5-year OS rate was 78% (95% CI: 73–84) vs. 82% (95% CI: 77–87) for the PC and GC group (HR = 1.63 (95% CI: 1.17–2.28), ). The predictive power was similar in another two testing sets (HR > 1.20, ). Finally, a nomogram is developed for clinical application, which integrated this signature and age to accurately predict the survival probability in BRCA patients. Conclusion. This 5-pathway signature correlated with immune-derived lncRNAs was able to precisely predict the prognosis for patients with BRCA and provided a rich source characterizing immune-related lncRNAs and further informed strategies to target BRCA vulnerabilities.
- 12 December 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-17
Open AccessA 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer
Background. Currently, predictive models were not developed based on the signaling pathway signatures of immune-related lncRNAs in breast cancer (BRCA) patients. Methods. We selected unsupervised hierarchical clustering algorithm to classify patients with BRCA based on the significant immune-derived lncRNAs from the TCGA dataset. And different methods including ESTIMATE, ImmuneCellAI, and CIBERSORT were performed to evaluate the immune infiltration of tumor microenvironment. Using Lasso regression algorithm, we filtered the significant signaling pathways enriched by GSEA, GSVA, or PPI analysis to develop a prognostic model. And a nomogram integrated with clinical factors and significant pathways was constructed to predict the precise probability of overall survival (OS) of BRCA patients in the TCGA dataset (n = 1,098) and another two testing sets (n = 415). Results. BRCA patients were stratified into the PC (n = 571) and GC (n = 527) subgroup with significantly different prognosis with 550 immune-related lncRNAs in the TCGA dataset. Integrated analysis revealed different immune response, oncogenic signaling, and metabolic reprograming pathways between these two subgroups. And a 5-pathway signature could predict the prognosis of BRCA patients between these two subgroups independently in the TCGA dataset, which was confirmed in another two cohorts from the GEO dataset. In the TCGA dataset, 5-year OS rate was 78% (95% CI: 73–84) vs. 82% (95% CI: 77–87) for the PC and GC group (HR = 1.63 (95% CI: 1.17–2.28), ). The predictive power was similar in another two testing sets (HR > 1.20, ). Finally, a nomogram is developed for clinical application, which integrated this signature and age to accurately predict the survival probability in BRCA patients. Conclusion. This 5-pathway signature correlated with immune-derived lncRNAs was able to precisely predict the prognosis for patients with BRCA and provided a rich source characterizing immune-related lncRNAs and further informed strategies to target BRCA vulnerabilities.
- 31 October 2022
- Published by Wiley in Expert Systems
- Vol. 40 (2)
Four‐gene signature based on machine learning filtration could predict prognosis of patients with breast cancer
Background: This study aims to propose a breast cancer prediction model for early diagnosis and prognosis management of breast cancer.Objective: In order to explore the pathogenesis of breast cancer and develop accurate breast cancer screening and treatment methods, we have used machine‐learning technologies to conduct an in‐depth study of breast cancer genetic data to obtain new breast cancer signature and prognostic prediction models.Methods: We explored an optimal cluster by unsupervised clustering methods with different expression genes (DEGs) between normal (n = 113) and tumour (n = 1,102) samples. Using least absolute shrinkage and selection operator (LASSO) regression, we selected four biomarkers to develop a predictive model by Cox regression method in the training set (n = 1,083) and validated its predictive accuracy and independence in the testing sets (n = 2,480). Then Gene Set Enrichment Analysis (GSEA) revealed enriched biological pathways in clusters. Finally, we constructed a nomogram including this signature and other significant risk factors to predict survival rates in patients.Results: Four mRNAs (CD163L1, QPRT, NKAIN1 and TP53AIP1) between two clusters from 4,938 DEGs were identified, and then a four‐gene model (risk scores = 0.454*CD163L1–0.360*NKAIN1 + 0.581*QPRT + 0.788*TP53AIP1) was established to divide patients into high‐ and low‐risk group with significantly different prognosis (p < 0.0001) in the training set. Integrated analysis revealed dysregulated molecular processes including predominantly oncogenic signalling pathway, cell cycle and DNA repair in high‐risk group but enriched metabolism pathway in low‐risk group. In addition, this model had similar predictive value (HR >1.60; p < 0.05) in three independent validation sets, which could predict survival independently with more power compared with single clinical factor. In addition, the nomogram could predict the prognosis of breast cancer patients precisely in the training set and another three testing sets.Conclusion: This model could predict prognosis of breast cancer patients precisely and independently, and provide evidence to make treatment decisions and design clinical trials.
- 31 October 2022
- Published by Wiley in Expert Systems
- Vol. 40 (2)
Four‐gene signature based on machine learning filtration could predict prognosis of patients with breast cancer
Background: This study aims to propose a breast cancer prediction model for early diagnosis and prognosis management of breast cancer.Objective: In order to explore the pathogenesis of breast cancer and develop accurate breast cancer screening and treatment methods, we have used machine‐learning technologies to conduct an in‐depth study of breast cancer genetic data to obtain new breast cancer signature and prognostic prediction models.Methods: We explored an optimal cluster by unsupervised clustering methods with different expression genes (DEGs) between normal (n = 113) and tumour (n = 1,102) samples. Using least absolute shrinkage and selection operator (LASSO) regression, we selected four biomarkers to develop a predictive model by Cox regression method in the training set (n = 1,083) and validated its predictive accuracy and independence in the testing sets (n = 2,480). Then Gene Set Enrichment Analysis (GSEA) revealed enriched biological pathways in clusters. Finally, we constructed a nomogram including this signature and other significant risk factors to predict survival rates in patients.Results: Four mRNAs (CD163L1, QPRT, NKAIN1 and TP53AIP1) between two clusters from 4,938 DEGs were identified, and then a four‐gene model (risk scores = 0.454*CD163L1–0.360*NKAIN1 + 0.581*QPRT + 0.788*TP53AIP1) was established to divide patients into high‐ and low‐risk group with significantly different prognosis (p < 0.0001) in the training set. Integrated analysis revealed dysregulated molecular processes including predominantly oncogenic signalling pathway, cell cycle and DNA repair in high‐risk group but enriched metabolism pathway in low‐risk group. In addition, this model had similar predictive value (HR >1.60; p < 0.05) in three independent validation sets, which could predict survival independently with more power compared with single clinical factor. In addition, the nomogram could predict the prognosis of breast cancer patients precisely in the training set and another three testing sets.Conclusion: This model could predict prognosis of breast cancer patients precisely and independently, and provide evidence to make treatment decisions and design clinical trials.
- Open Access
- 18 September 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (9) , e1029
Integrative analysis identifies three molecular subsets in ovarian cancer
- 18 September 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (9) , e1029
Open AccessIntegrative analysis identifies three molecular subsets in ovarian cancer